Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real‐time two‐dimensional shear wave elastography: A randomized clinical trial. (9th November 2020)

• Record Type: Journal Article
• Authors: Soleimani, Davood; Rezaie, Mitra; Rajabzadeh, Farnood; Gholizadeh Navashenaq, Jamshid; Abbaspour, Mohammadreza; Miryan, Mahsa; Razmpour, Farkhondeh; Ranjbar, Golnaz; Rezvani, Reza; Jarahi, Lida; Hashemy, Seyed Isaac; Goshayeshi, Ladan; Nematy, Mohsen
• Is Part Of: Phytotherapy research. Volume 35:Number 3(2021)
• Page Start: 1669
• Page End: 1679
• Publication Date: 2020-11-09
• Subjects: elastography -- fibrosis -- liver stiffness -- non‐alcoholic fatty liver disease -- propolis -- steatosis; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.6937
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract : Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, while no drugs have been approved for its treatment. The pieces of evidence indicate that propolis as a novel anti‐inflammatory agent might be a promising candidate to treat NAFLD. We aimed to evaluate the efficacy of propolis on hepatic steatosis and fibrosis in patients with NAFLD. This randomized clinical trial was conducted on 54 patients with NAFLD. Patients were randomly assigned to receive propolis tablets at a dose of 250 mg twice daily for 4 months or placebo. The improvement in hepatic steatosis and fibrosis was evaluated using two‐dimensional shear wave elastography. Improvement in the hepatic steatosis was significantly higher in the propolis group than the placebo group, even after adjustment for baseline value and changes in weight, energy intake, and physical activity (odds ratio [OR]: 5.67; 95% confidence intervals [CI]: 1.41–22.8; p = .014). A significant reduction was observed on the liver stiffness in the propolis group (−0.65 ± 0.56 kPa; p = .001), whereas it increased in the placebo group (0.27 ± 0.59 kPa; p = .037). Also, the intake of propolis significantly decreased high‐sensitivity C‐reactive protein (hs‐CRP) levels compared with the placebo group (−0.371; 95%CI: −0.582 to −0.16 mg/L; p = .01). Changes in serum levels of fasting blood sugar, alanine aminotransferase, aspartate aminotransferase, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, cholesterol, and triglyceride did not differ significantly between the two groups ( p > .05). There was no significant improvement in insulin resistance in both groups ( p > .05). Propolis seems to have protective effects on hepatic steatosis and fibrosis and to reduce the serum levels of hs‐CRP in patients with NAFLD.